Drug Trial Radar · NCT06421935
M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Actual
Start
Aug 7, 2024
Primary completion
Feb 22, 2027
Study completion Feb 22, 2027
Sponsor
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- May 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic profile of M9466 with and without tuvusertib or an ARPi and early signs of clinical activity of M9466 with tuvusertib in participants with advanced solid tumors. Study details include: Study/Treatment Duration: Participants will be treated until disease progression, death, discontinuation, or End of Study. Visit Frequency: Every week in the first 2 cycles, followed by every 3 weeks in the subsequent cycles. An End of Treatment Visit and Safety Follow-up/Discontinuation Visit are scheduled after the treatment period.
Conditions
- Advanced Solid Tumor
Interventions
M9466Drug
Participants will be administered M9466 orally.
TuvusertibDrug
Participants will be administered Tuvusertib orally.
Abiraterone acetateDrug
Participants will be administered with Abiraterone acetate orally.
Prednisone/PrednisoloneDrug
Participants will be administered with prednisone/prednisolone orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Module 1 Part A1 and Part A2: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Treatment-related AEs (TRAEs)Time frame: Time from first treatment up to 30 days after end of study intervention (approximately assessed up to 20 months)
- Module 1 Part A1 and Part A2: Number of Participants with Dose Limiting Toxicity (DLT)-like eventsTime frame: Day 1 up to Day 21 of Cycle 1 (each cycle is of 21 days)
- Module 2 Part A1: Pharmacokinetic (PK) Plasma Concentrations of M9466Time frame: Cycle 1 Day 1 (C1D1), C1D8 and C1D15
- Module 2 Part A2: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Treatment-related AEs (TRAEs)Time frame: Time from first treatment up to 30 days after end of study intervention (approximately assessed up to 20 months)
- Module 3 Part A1: Number of Participants With Treatment-Emergent Adverse Events (TEAE), and Treatment-related AEsTime frame: Time from first treatment up to 30 days after end of study intervention
- Module 3 Part A1: Number of Participants with Dose Limiting Toxicity (DLT)-like EventsTime frame: Day 1 up to Day 21 of Cycle 1(each cycle is of 21 days)
Locations
20 sites in 5 countries. Site status is shown where the registry gives one.
NEXT Oncology - PARENT
New York, New York
The University of Texas MD Anderson Cancer Center
Houston, Texas
Cancer Research SA
Adelaide, Australia
GenesisCare North Shore (Oncology)
St Leonards, Australia
Harasanshin Hospital
Fukuoka, Japan
National Cancer Center Hospital East - Dept of Experimental Therapeutics
Kashiwa-shi, Japan
Cancer Institute Hospital of JFCR
Kōtoku, Japan
NHO Kumamoto Medical Center - Dept of Urology
Kumamoto, Japan
Seoul National University Bundang Hospital
Seongnam, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital, Yonsei University Health System - Division of Infectious Diseases
Seoul, South Korea
Hospital HM Nou Delfos - START Barcelona
Barcelona, Spain
Hospital Universitari Vall d'Hebron - Oncology Dept.
Barcelona, Spain
ICO l'Hospitalet - Hospital Duran i Reynals - Servicio de Oncologia
Barcelona, Spain
Centro Integral Oncologico Clara Campal - Unidad de Fase I-Oncologica
Madrid, Spain
Hospital Universitario 12 de Octubre - Servicio de Oncologia
Madrid, Spain
Hospital Universitario Fundacion Jimenez Diaz - START Madrid FJD - Oncology Phase I
Madrid, Spain
NEXT Madrid - Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.